Table 2.
Baseline characteristics of the study and control group.
| Baseline characteristics/additional diagnosis/ medications/Framingham score | Cyanotic patients (n = 36) | Control group (n = 30) | Cyanotic patients vs. control group (p-value) |
|---|---|---|---|
| Baseline characteristics | |||
| Male: female | 12:24 | 11:19 | 0.8 |
| Age (years) | 38 (19–73) | 38.5 (26–59) | 0.9 |
| Oxygen blood saturation (%) | 87.5 (65–91) | 99 (96–99) | <0 . 001 |
| Body mass index (kg/m2) | 22 (15.4–43) | 24 (18.8–36) | 0 . 02 |
| Systolic blood pressure | 107.5 (90–160) | 122.5 (100–175) | <0 . 001 |
| Diastolic blood pressure | 75 (60–100) | 80 (60–100) | 0.3 |
| Additional diagnosis | |||
| Smokers, n (%) | 2 (5.6) | 3 (10) | 0.5 |
| Diabetes mellitus, n (%) | 2 (5.6) | 0 (0) | 0.2 |
| Stroke, n (%) | 4 (11.1) | 0 (0) | 0.06 |
| Overweight, n (%) | 7 (19.4%) | 9 (30) | 0.3 |
| Obesity, n (%) | 1 (2.8) | 1 (3.3) | 0.9 |
| Medications | |||
| Statins, n (%) | 4 (11.1) | 2 (6.7) | 0.5 |
| Advanced therapy for pulmonary arterial hypertension, n (%) | 14 (38.9) | 0 (0) | 0 . 001 |
| Endothelin receptor antagonist, n (%) | 13 (36.1) | 0 (0) | 0 . 001 |
| Phosphodiesterase 5 inhibitor, n (%) | 12 (33.3) | 0 (0) | 0 . 001 |
| Prostcyclin analogs, n (%) | 1 (2.8) | 0 (0) | 0 . 001 |
| Framingham 10-year CVD risk scorea | |||
| Low <10%, n (%) | 25 (69.4%) | 18 (60%) | p = 0.7a |
| Medium 10–19%, n (%) | 1 (2.8%) | 3 (10%) | |
| High ≥20%, n (%) | 2 (5.6%) | 1 (3.3%) | |
| Patients <30 years-old, n (%) | 8 (22.2%) | 8 (26.7%) | |
CVD, cardiovascular heart disease; diam, diameter; IVS, intraventricular septum; LA, left atrium; LV -left ventricle; LVEF, left ventricle ejection fraction; LW, lateral wall; PW, posterior wall; RV, right ventricle; TRV, peak tricuspid regurgitant velocity. Bold values are statistically significant.
a
Framingham 10-year CVD risk score is suitable only for patients older than 30; younger patients were omitted.